Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.72 |
| ▸ | CA12 | O43570 | 6/20 | 0.66 |
| ▸ | CA1 | P00915 | 6/20 | 0.66 |
| ▸ | CA2 | P00918 | 6/20 | 0.66 |
| ▸ | CA9 | Q16790 | 6/20 | 0.66 |
| ▸ | PKM | P14618 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | ABL1 | P00519 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | IDE | P14735 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | HLCS | P50747 | 3/20 | 0.57 |
| ▸ | F2 | P00734 | 1/20 | 0.57 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.57 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.57 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.57 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26598596 | 1.00 | TDP1 (0.72) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL30821562 | 1.00 | TDP1 (0.72) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL10140274 | 1.00 | TDP1 (0.72) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL25014977 | 1.00 | TDP1 (0.72) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL10000338 | 1.00 | TDP1 (0.72) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL24420141 | 1.00 | TDP1 (0.72) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL15895090 | 1.00 | TDP1 (0.72) | TDP1CA12CA1CA2CA9 | |
| Ethylenediamine SCHEMBL16679417 | 0.99 | TDP1 (0.70) | TDP1CA12CA1CA2CA9 | |
| Bromide SCHEMBL2678585 | 0.99 | TDP1 (0.70) | TDP1CA12CA1CA2CA9 | |
| Hydrochloric Acid SCHEMBL8147632 | 0.99 | TDP1 (0.70) | TDP1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119986004-A | Milligram-grade drug-resistant antibody detection method and detection kit | 北京新艾进生物科技有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-107849089-B | Solution phase synthesis and crystallization of beta-turn cyclic peptidomimetic salts | 米梅奥亨制药公司 | 2022-07-05 | — | — | CN | claimed |
| CN-111269164-B | Ketone compound, preparation method and application thereof, and method for site-directed modification of protein containing cysteine residues or disulfide bonds | 南开大学 | 2021-11-02 | — | — | CN | claimed |
| EP-4065619-B1 | BIOTIN-CONTAINING MONOMERS AND ARTICLES FORMED THEREFROM | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-116773831-B | Method, reagent and kit for measuring sterols in lipoproteins | 希森美康株式会社 | 2026-05-15 | — | — | CN | disclosed |
| EP-4246147-B1 | METHOD FOR MEASURING STEROL IN LIPOPROTEIN, AND REAGENT FOR MEASURING STEROL IN LIPOPROTEIN | SYSMEX CORP (JP) | 2026-05-06 | — | — | EP | disclosed |
| US-12528824-B2 | Biotin-containing monomers and articles formed therefrom | Thermo Fisher Bioprocessing Inc. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250381168-A1 | VLA4 INHIBITORS AND USES THEREOF | WASHINGTON UNIVERSITY ST LOUIS (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250367307-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND/OR PREVENTION | TORAY INDUSTRIES, INC. (JP) | 2025-12-04 | — | — | US | disclosed |
| US-20250345446-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | DRAUPNIR BIO APS (DK) | 2025-11-13 | — | — | US | disclosed |
| US-20250339542-A1 | CONVERSION OF A BIOLOGICALLY SILENT MIRNA BINDING SMALL MOLECULE TO AN MIRNA DEGRADER | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-11-06 | — | — | US | disclosed |
| US-20020187249-A1 | Process for the production of surface-functionalized supports that serve as starting materials for microarrays used for immobilizing biomolecules | PLUSTER WILHELM (US) | 2002-12-12 | — | — | US | disclosed |
| US-6462041-B1 | ACTIVATORS OF CASPASE CASCADE; TREATING, PREVENTING OR AMELIORATING NEOPLASIA AND CANCER | CYTOVIA, INC. | 2002-10-08 | — | — | US | disclosed |
| EP-1204488-A1 | METHOD FOR PRODUCING SURFACE-FUNCTIONALIZED SUPPORTS USED AS STARTING PRODUCTS FOR MICROARRAYS, FOR IMMOBILIZING BIOMOLECULES | EPPENDORF AG (DE) | 2002-05-15 | — | — | EP | disclosed |
| EP-1180991-A2 | GAMBOGIC ACID, ANALOGS AND DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Cytovia, Inc. (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2001094032-A1 | METHOD FOR PRODUCING SURFACE-FUNCTIONALIZED SUPPORTS USED AS STARTING PRODUCTS FOR MICROARRAYS, FOR IMMOBILIZING BIOMOLECULES | EPPENDORF AG (DE) | 2001-12-13 | — | — | WO | disclosed |
| WO-2000044216-A2 | GAMBOGIC ACID, ANALOGS AND DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2000-08-03 | — | — | WO | disclosed |
| US-6030846-A | Homogeneous assays using avidin-binding azo reagents | DADE BEHRING INC. (US) | 2000-02-29 | — | — | US | disclosed |
| US-5612221-A | Avidin-binding fluorescing and quenching reagent for use in homogeneous assays | DADE CHEMISTRY SYSTEMS INC. (US) | 1997-03-18 | — | — | US | disclosed |
| US-5536820-A | Avidin-binding azo reagents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345446-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | SORT1, SCARB1, LAMP1 | TDP1 2734/4885CA12 4066/4885CA1 4441/4885 |
| US-20250367307-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND/OR PREVENTION | CAPRIN1, NOS1, NCBP1 | TDP1 975/4885CA12 2469/4885CA1 828/4885 |
| US-20250339542-A1 | CONVERSION OF A BIOLOGICALLY SILENT MIRNA BINDING SMALL MOLECULE TO AN MIRNA DEGRADER | NSUN3, AGO2, ZFR | TDP1 1666/4885CA12 3388/4885CA1 3908/4885 |
| US-12528824-B2 | Biotin-containing monomers and articles formed therefrom | PBRM1, ICAM1, EPCAM | TDP1 3688/4885CA12 2120/4885CA1 3095/4885 |
| US-20250381168-A1 | VLA4 INHIBITORS AND USES THEREOF | CXCR4, SDF4, ITGB4 | TDP1 3968/4885CA12 2667/4885CA1 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.